FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

FDA AGAINST THE FLASH MOB


Last week the parents of 7-year-old Josh Hardy managed to whip up a media tempest big enough to get the biotech Chimerix  and the FDA to work out a pilot study so that their child could be treated after their compassionate use request was denied, alongside many others. Now the parents of another young boy afflicted by a terrible disease are using some interesting PR tactics in an attempt to achieve a much larger goal: Push the FDA to approve experimental drugs for Duchenne muscular dystrophy (DMD) ahead of pivotal studies in the hope that it could let their young son, Ryan Dunne, live a "healthy life."


The local CBS affiliate in Colorado turned out for a flash mob demonstration yesterday with protesters chanting Ryan's name,  and giving his parents a chance to highlight their campaign to get 100,000 signatures together to push the FDA to make unapproved DMD drugs available to a young patient population with no therapies approved for the ultimately lethal muscle-wasting disease. Other parents have been turning out in large groups to give FDA officials an earful on the same point. And the "Race to Yes" campaign today added heat with their own statement backing the petition, which is specifically designed to get an accelerated approval for Sarepta's ($SRPT) eteplirsen.

"We don't have time to wait for the FDA," says Jennifer Dunne in her appeal at helpryandunne.com. "We need to do it now," says Ryan's father, adding that his son can't wait years for the FDA to act.

"Every day that the FDA stalls, Duchenne takes children's lives," said Tracy Seckler, the parent of a child with DMD, in a statement. "The FDA claims this is a priority, but they've been sending us the same bureaucratic form letter for several months. If they grant accelerated approval, our children could be the first generation of Duchenne patients to survive."

The campaign raises compelling questions. Does the FDA have a responsibility to allow children access to unproven drugs, provided there's evidence of their safety and the possibility of a positive outcome--of any kind? A group of companies, in particular Sarepta, Prosensa ($RNA) and PTC Therapeutics ($PTCT), have all provided some signals from the data that could indicate a benefit. But Sarepta only has data from a tiny study the agency has already questioned, looking to a pivotal study to decide whether the drug really works. Prosensa's drug failed a Phase III study conducted by GlaxoSmithKline ($GSK). PTC's earlier study for DMD also failed. And all three biotechs insist that there are compelling signs that the drugs may work for some of these boys.

If the FDA eventually decides to capitulate on this point, the biotechs would have a chance to market drugs to children. That could set up another showdown with restive private payers which may well reject covering drugs that are green-lighted without solid evidence of efficacy, approved under traditional guidelines. And that might leave parents to pay a high cost for unproven medications which may have no more effect on the disease than a placebo.

Parents and children don't want to hear about traditional guidelines when they reflect on what's happening to their child. The public will side with the victims, and that leaves the FDA caught between the high R&D standards it's mandated to uphold and the passions aroused by parents, the victims of disease and protesters.
source
CLICK HERE TO WATCH VIDEO


Go to Newer News Go to Older News